2019
DOI: 10.1016/j.pdpdt.2019.06.017
|View full text |Cite
|
Sign up to set email alerts
|

Novel strategy to increase specificity of ALA-Induced PpIX accumulation through inhibition of transporters involved in ALA uptake

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 34 publications
0
6
0
Order By: Relevance
“…After its entry into the cell, ALA is converted into PpIX and heme through a series of enzyme-mediated reactions in the cell [ 22 , 23 ]. The uptake of ALA into the cell can be determined by measuring the concentration of PpIX and heme produced using high performance liquid chromatography (HPLC) as described in the Materials & Methods.…”
Section: Resultsmentioning
confidence: 99%
“…After its entry into the cell, ALA is converted into PpIX and heme through a series of enzyme-mediated reactions in the cell [ 22 , 23 ]. The uptake of ALA into the cell can be determined by measuring the concentration of PpIX and heme produced using high performance liquid chromatography (HPLC) as described in the Materials & Methods.…”
Section: Resultsmentioning
confidence: 99%
“…The effect of PDT is closely related to the concentration of photosensitizers and the time of application (17). This mechanism helps PDT specifically targets and inhibits actively proliferating pathological cells, which makes it a promising alternative to cervical precancerous diseases due to its high efficacy and minimal side effects (18). Following the administration of exogenous PSs,…”
Section: Discussionmentioning
confidence: 99%
“…Western blotting analyses were carried out as previously described ( Lai et al, 2019 ). We used polyclonal anti-human Ki-67 antibody (Abcam, Cambridge, UK; 1:1000), anti-human p21 antibody (Invitrogen, Waltham, MA, USA, 1:500), anti-human CD44 antibody (Abcam, Cambridge, UK; 1:200), anti-human GLUT1 antibody (Abcam, Cambridge, MA, USA; 1:500), anti-human GAT2 antibody (Medical & Biological Laboratories, Nagoya, Japan; 1:1000), and anti-human HSP90 antibody (Santa Cruz Biotechnology, TX, USA; 1:200 dilution) as primary antibodies.…”
Section: Methodsmentioning
confidence: 99%